{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:10:25Z","timestamp":1760850625619,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nucmedbio.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:10:20Z","timestamp":1618999820000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice"],"prefix":"10.1016","volume":"98-99","author":[{"given":"Sadaf","family":"Aghevlian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Nura","family":"Raie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer K.","family":"Tumbale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris J.","family":"Kare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai W.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine W.","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/21645515.2019.1653744","article-title":"Concepts for agonistic targeting of CD40 in immuno-oncology","volume":"16","author":"Richards","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0010","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12776","article-title":"Copy number of the X-linked genes TLR7 and CD40L influences innate and adaptive immune responses","volume":"90","author":"Sarmiento","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-115","article-title":"A CD40 agonist potentiates the efficacy and immune-stimulatory capacity of chemotherapy in combination with a focal adhesion kinase inhibitor in a mouse model of pancreatic ductal adenocarcinoma","volume":"79","author":"Stone","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0025","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1073\/pnas.1810566115","article-title":"Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity","volume":"115","author":"Knorr","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0040","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20171440","article-title":"Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity","volume":"215","author":"Hoves","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0045","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1158\/0008-5472.CAN-16-2089","article-title":"CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations","volume":"77","author":"Nimanong","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0050","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1084\/jem.20171435","article-title":"Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity","volume":"215","author":"Perry","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00262-018-2115-2","article-title":"Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors","volume":"67","author":"Ward-Kavanagh","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/2326-6066.CIR-18-0448","article-title":"Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma","volume":"7","author":"Stromnes","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0075","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1084\/jem.20031591","article-title":"Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN","volume":"199","author":"Ahonen","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.intimp.2018.03.038","article-title":"Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis","volume":"59","author":"Caisova","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0100","first-page":"262","article-title":"Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro","volume":"28","author":"He","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0105","first-page":"2085","article-title":"CD40 expression in pancreatic cancer","volume":"60","author":"Unek","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0110","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0115","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0125","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1182\/blood.V106.11.2572.2572","article-title":"A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma","volume":"106","author":"Drachman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"Ruter","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0150","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0155","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.23712","article-title":"Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer","volume":"113","author":"Kawai","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0160","first-page":"1060","article-title":"Development of 89Zr-avelumab for clinical studies","volume":"60","author":"Wei","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0170","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2014.57.8278","article-title":"Antibody positron emission tomography imaging in anticancer drug development","volume":"33","author":"Lamberts","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.915","article-title":"P1.04-12 tumor uptake and biodistribution of 89Zr-labeled pembrolizumab in patients with metastatic non-small-cell lung cancer","volume":"14","author":"Niemeijer","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0180","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.2967\/jnumed.109.065862","article-title":"Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients","volume":"50","author":"Borjesson","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","article-title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","volume":"51","author":"Holland","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0190","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-17-0855","article-title":"ImmunoPET of malignant and normal B cells with 89Zr- and 124I-labeled obinutuzumab antibody fragments reveals differential CD20 internalization in vivo","volume":"23","author":"Zettlitz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","article-title":"A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals","volume":"71","author":"Sharma","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0200","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0205","first-page":"713","article-title":"Radiation dosimetry of 131I-19-iodocholesterol","volume":"14","author":"Kirschner","year":"1973","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0210","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/acs.molpharmaceut.8b01040","article-title":"Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NRG mice with panitumumab modified with metal-chelating polymers complexed to 177Lu","volume":"16","author":"Aghevlian","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-020-00111-y","article-title":"Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD\/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or beta-particle emitting, 177Lu","volume":"5","author":"Aghevlian","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0220","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0225","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1097\/MNM.0000000000000590","article-title":"Pharmacokinetics and microbiodistribution of 64Cu-labeled collagen-binding peptides in chronic myocardial infarction","volume":"37","author":"Kim","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0230","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.nucmedbio.2012.05.009","article-title":"Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development","volume":"39","author":"De Silva","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0235","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/bc300037w","article-title":"Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro\/in vivo stability","volume":"23","author":"Cooper","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.04.001_bb0240","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2967\/jnumed.107.043703","article-title":"PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer","volume":"49","author":"Zhang","year":"2008","journal-title":"J Nucl Med"},{"year":"2020","series-title":"CFR - Code of Federal Regulations title 21","key":"10.1016\/j.nucmedbio.2021.04.001_bb0245"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:35Z","timestamp":1760848175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805121000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":47,"alternative-id":["S0969805121000561"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.04.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}